Lys-MDA, or lysine-MDA, also known as N-(L-lysinamidyl)-MDA, is an entactogen of the phenethylamine, amphetamine, and MDxx families with entactogenic effects, which acts as a prodrug for MDA with a somewhat slower onset of effects and longer duration of action. Lys-MDA, along with the related derivative Lys-MDMA, are in early stage human clinical trials as potential treatments for treatment-resistant depression and post-traumatic stress disorder. New MDMA prodrugs are in the development phase at MiHKAL GmbH in Switzerland. A phase 1 clinical trial comparing MDMA, MDA, Lys-MDMA, and Lys-MDA has been completed as of August 2024. The trial results, which included pharmacodynamic and pharmacokinetic findings, was published in September 2025.
Interactions
See also Substituted methylenedioxyphenethylamine List of investigational hallucinogens and entactogens Lisdexamfetamine Serdexmethylphenidate N-t-BOC-MDMA Lomardexamfetamine
References
External links Lysine-MDA (Lys-MDA) - Isomer Design